多柔比星的耐药机制

doi:10.3760/cma.j.issn.1673-422X.2013.12.002

摘要/Abstract

摘要： 多柔比星广泛应用于乳腺癌等肿瘤的化疗中，但因耐药使其应用受到一定限制。多柔比星耐药的产生机制可能涉及转运蛋白、凋亡蛋白、DNA修复功能、酶等因素。逆转多柔比星耐药的研究也在持续进行，为临床上克服多柔比星耐药提供了有效方案。但具体机制仍有待进一步阐释，并期待提出更合理的策略以提高疗效。

关键词: 抗药性, 肿瘤, 多柔比星

Abstract: Doxorubicin is widely used in chemotherapy of breast cancer and many other cancers. However, doxorubicin resistance restricts its use to some extent. The mechanisms of doxorubicin resistance may involve transport protein, apoptosis protein, DNA repair function, enzyme and other factors. Researches about reversing doxorubicin resistance are ongoing and provide some effective therapeutic regimens to overcome doxorubicin resistance clinically. But the specific mechanism of doxorubicin resistance is yet to be elucidated. It is expected that more reasonable and effective countermeasures will be put forward to improve the theraputical effect of doxorubicin.

Key words: Drug resistance, neoplasm, Doxorubicin

冼志荣, 张国君. 多柔比星的耐药机制[J]. 国际肿瘤学杂志, 2013, 40(12): 886-889.

XIAN Zhi-Rong, ZHANG Guo-Jun. Resistant mechanisms of doxorubicin[J]. Journal of International Oncology, 2013, 40(12): 886-889.

参考文献

［1］ Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta, 2009, 1794(5): 860871. ［2］ Xu HB, Li L, Fu J, et al. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by βelemene. Pharmacology, 2012, 89(56): 303312. ［3］ Zhu MM, Tong JL, Xu Q, et al. Increased JNK1 signaling pathway is responsible for ABCG2mediated multidrug resistance in human colon cancer. PLoS One, 2012, 7(8): e41763. ［4］ O′Malley FP, Chia S, Tu D, et al. Topoisomerase Ⅱ alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst, 2009， 101(9): 644650. ［5］ Du Y, Zhou Q, Yin W, et al. The role of topoisomerase Ⅱα in predicting sensitivity to anthracyclines in breast cancer patients: a metaanalysis of published literatures. Breast Cancer Res Treat, 2011, 129(3): 839848. ［6］ Taylor JR, Lehmann BD, Chappell WH, et al. Cooperative effects of Akt1 and Raf1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget, 2011, 2(8): 610626. ［7］ Trape AP, Katayama ML, Roela RA, et al. Gene expression profile in response to doxorubicinrapamycin combined treatment of HER2overexpressing human mammary epithelial cell lines. Mol Cancer Ther, 2012, 11(2): 464474. ［8］ El Azreq MA, Naci D, Aoudjit F. Collagen/β1 integrin signaling upregulates the ABCC1/MRP1 transporter in an ERK/MAPKdependent manner. Mol Biol Cell, 2012, 23(17): 34733484. ［9］ Shen H, Xu W, Luo W, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB1 nuclear translocation in Bcell lymphoma. Exp Hematol, 2011, 39(5): 558569. ［10］ Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D,Llactidecoglycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm, 2011, 8(3): 852866. ［11］ Wang MY, Chen PS, Prakash E, et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant upregulation of BclxL and cIAP1. Cancer Res, 2009, 69(8): 34823491. ［12］ Knappskog S, Chrisanthar R, Lokkevik E, et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res, 2012, 14(2): R47. ［13］ Wang X, Wu X, Wang C, et al. Transcriptional suppression of breast cancer resistance protein (BCRP) by wildtype p53 through the NFkappaB pathway in MCF7 cells. FEBS Lett, 2010, 584(15): 33923397. ［14］ Tian B, Liu J, Liu B, et al. p53 suppresses lung resistancerelated protein expression through Ybox binding protein 1 in the MCF7 breast tumor cell line. J Cell Physiol, 2011, 226(12): 34333441. ［15］ Pardee TS. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLoS One, 2012, 7(8): e43185. ［16］ Hilton J, Weberpals J, Lorimer I, et al. BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: an exploratory analysis. Oncol Lett, 2012, 4(1): 141145. ［17］ Zhang Y, Wang H, Wei L, et al. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat, 2010, 123(3): 679689. ［18］ Hartz AM, Madole EK, Miller DS, et al. Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3kinase/Akt/glycogen synthase kinase 3 downregulates bloodbrain barrier breast cancer resistance protein. J Pharmacol Exp Ther, 2010, 334(2): 467476. ［19］ Zhu X, He Z, Wu J, et al. A marine anthraquinone SZ685C overrides adriamycinresistance in breast cancer cells through suppressing Akt signaling. Mar Drugs, 2012, 10(4): 694711. ［20］ Donmez Y, Akhmetova L, Iseri OD, et al. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicinresistant MCF7 cells. Cancer Chemother Pharmacol, 2011, 67(4): 823828. ［21］ Shen Y, Chu Y, Yang Y, et al. Mitochondrial localization of Pglycoprotein in the human breast cancer cell line MCF7/ADM and its functional characterization. Oncol Rep, 2012, 27(5): 15351540. ［22］ Liu G, Wang R, Wang Y, et al. Ethacrynic acid oxadiazole analogues induce apoptosis in malignant hematological cells through downregulation of Mcl1 and cFLIP which was attenuated by GSTP11. Mol Cancer Ther, 2013, 12(9): 111. ［23］ Wang F, Liu HM, Irwin MG, et al. Role of protein kinase C beta2 activation in TNFalphainduced human vascular endothelial cell apoptosis. Can J Physiol Pharmacol, 2009, 87(3): 221229.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.